ATE378418T1 - Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen - Google Patents

Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen

Info

Publication number
ATE378418T1
ATE378418T1 AT99953081T AT99953081T ATE378418T1 AT E378418 T1 ATE378418 T1 AT E378418T1 AT 99953081 T AT99953081 T AT 99953081T AT 99953081 T AT99953081 T AT 99953081T AT E378418 T1 ATE378418 T1 AT E378418T1
Authority
AT
Austria
Prior art keywords
rage
peptide
interaction
compound
inhibiting
Prior art date
Application number
AT99953081T
Other languages
English (en)
Inventor
Ann Schmidt
David Stern
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/167,705 external-priority patent/US7081241B1/en
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of ATE378418T1 publication Critical patent/ATE378418T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
AT99953081T 1998-10-06 1999-10-06 Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen ATE378418T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/167,705 US7081241B1 (en) 1998-10-06 1998-10-06 Extracellular rage binding protein (EN-RAGE) and uses thereof
US09/263,312 US6555340B1 (en) 1998-10-06 1999-03-05 Nucleic acid encoding bovine extracellular rage binding protein (en-rage)

Publications (1)

Publication Number Publication Date
ATE378418T1 true ATE378418T1 (de) 2007-11-15

Family

ID=26863404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99953081T ATE378418T1 (de) 1998-10-06 1999-10-06 Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen

Country Status (9)

Country Link
US (3) US6670136B2 (de)
EP (1) EP1121454B1 (de)
JP (1) JP2002526117A (de)
AT (1) ATE378418T1 (de)
AU (1) AU765719B2 (de)
CA (1) CA2346217A1 (de)
ES (1) ES2299267T3 (de)
HK (1) HK1041293B (de)
WO (1) WO2000020621A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6482932B1 (en) * 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6617438B1 (en) * 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6528640B1 (en) * 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
EP1121454B1 (de) * 1998-10-06 2007-11-14 The Trustees of Columbia University in the City of New York Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
CN1494425B (zh) 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
JP2004523565A (ja) 2001-03-05 2004-08-05 トランス　テック　ファーマ，インコーポレイテッド 治療因子としてのベンゾイミダゾール誘導体
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
ATE529110T1 (de) 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
DE602004017148D1 (de) 2003-03-28 2008-11-27 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
CA2559723C (en) * 2004-03-18 2010-02-23 Transtech Pharma, Inc. Fluorescence polarization assay related applications
EP1771565B1 (de) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivate
AU2005271452B2 (en) 2004-08-03 2011-11-03 Vtv Therapeutics Llc RAGE fusion proteins and methods of use
CN101010430A (zh) * 2004-08-03 2007-08-01 转化技术制药公司 Rage融合蛋白及使用方法
US20090220484A1 (en) * 2005-03-17 2009-09-03 Ann Marie Schmidt Rage/Diaphanous Interaction and Related Compositions and Methods
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
EP1963786B1 (de) * 2005-12-23 2013-07-24 GCoder Systems AB Positionierungsmuster
AU2007215503A1 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
WO2007130302A2 (en) 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
JP2011502244A (ja) * 2007-10-19 2011-01-20 エラック エイエス Ｅｄｔａ耐性ｓ１００ａ１２複合体（ｅｒａｃ）
KR20120127543A (ko) 2008-05-23 2012-11-21 시와 코퍼레이션 재생을 촉진하는 방법, 조성물 및 장치
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
JP5805646B2 (ja) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー アルツハイマー病の治療のための置換イミダゾール誘導体
ES2550667T3 (es) 2010-02-18 2015-11-11 Vtv Therapeutics Llc Derivados de fenilheteroarilo y métodos de uso de los mismos
US20110287458A1 (en) * 2010-05-18 2011-11-24 The Texas A&M University System Method and composition for the diagnosis and monitoring of inflammatory diseases
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
CA2838284C (en) * 2011-06-04 2017-10-24 Rochester General Hospital Research Institute Methods relating to s100a12 for diagnosing infectious diseases and kit therefor
WO2013103688A1 (en) * 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human soluble receptors for advanced glycation end products (srage), methods of preparing human srage, and treatment methods using srage
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
RU2721568C2 (ru) 2014-09-19 2020-05-20 Сива Корпорейшн Анти-age антитела для лечения воспаления и аутоиммунных нарушений
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
CN109071675A (zh) 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
EP3475306A1 (de) 2016-06-23 2019-05-01 Siwa Corporation Impfstoffe zur verwendung bei der behandlung verschiedener erkrankungen und störungen
EP3487874A1 (de) 2016-07-20 2019-05-29 Westfälische Wilhelms-Universität Münster Komplexspezifische standardisierung von immunologischen verfahren zur quantifizierung von s100a12
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
EP3609923A1 (de) 2017-04-13 2020-02-19 Siwa Corporation Humanisierter monoklonaler advanced-glycation-endproduct-antikörper
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN115996954A (zh) * 2020-05-01 2023-04-21 Siwa有限公司 治疗感染的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0731166A3 (de) * 1995-03-06 1997-12-29 Tonen Corporation Neue Calcium-bindende Proteine
JPH08238090A (ja) * 1995-03-06 1996-09-17 Jiro Hitomi 新規カルシウム結合タンパク
JPH08238091A (ja) * 1995-03-06 1996-09-17 Jiro Hitomi 新規カルシウム結合タンパク
US5976832A (en) * 1995-03-06 1999-11-02 Tonen Corporation DNA encoding novel calcium-binding proteins
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US5688653A (en) * 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
EP1121454B1 (de) * 1998-10-06 2007-11-14 The Trustees of Columbia University in the City of New York Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
WO2001012598A2 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
US6825164B1 (en) * 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US6563015B1 (en) * 2000-08-14 2003-05-13 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
EP1660014A4 (de) * 2003-09-05 2009-07-22 Univ Columbia Rage-verwandte verfahren und zusammensetzungen zur behandlung von glomerulären schäden
US20070167360A1 (en) * 2003-10-31 2007-07-19 Yan Shi D Methods for treating multiple sclerosis
US20080260717A1 (en) * 2003-10-31 2008-10-23 Trustees Of Columbia University In The City Of New York Methods for Reducing Seizure-Induced Neuronal Damage
CN101010430A (zh) * 2004-08-03 2007-08-01 转化技术制药公司 Rage融合蛋白及使用方法
US20090220484A1 (en) * 2005-03-17 2009-09-03 Ann Marie Schmidt Rage/Diaphanous Interaction and Related Compositions and Methods
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases

Also Published As

Publication number Publication date
WO2000020621A1 (en) 2000-04-13
HK1041293A1 (en) 2002-07-05
ES2299267T3 (es) 2008-05-16
AU765719B2 (en) 2003-09-25
US20090228997A1 (en) 2009-09-10
US6670136B2 (en) 2003-12-30
US20040121372A1 (en) 2004-06-24
US20020106726A1 (en) 2002-08-08
EP1121454A1 (de) 2001-08-08
EP1121454A4 (de) 2005-05-11
JP2002526117A (ja) 2002-08-20
EP1121454B1 (de) 2007-11-14
HK1041293B (en) 2008-01-25
CA2346217A1 (en) 2000-04-13
AU6510099A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
ATE378418T1 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
EP1903058A3 (de) Extrazelluläres neues RAGE-bindendes Protein (EN-RAGE) und dessen Verwendung
Svenningsen et al. Mechanisms of renal NaCl retention in proteinuric disease
Jeay et al. Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53–MDM2 inhibitor HDM201
Svenningsen et al. Plasmin in nephrotic urine activates the epithelial sodium channel
Serrano‐Candelas et al. Comparable actions of omalizumab on mast cells and basophils
Cemerski et al. Oxidative‐stress‐induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules
Qu et al. The Ser219–> Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype
Carbotti et al. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors
Liu et al. Transient receptor potential channels in essential hypertension
ATE368853T1 (de) Zell-selektives abgabe system
HK1040533A1 (zh) 监察蛋白脢体抑制剂药物活动的方法
Dendorfer et al. Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats
Vergaro et al. Prognostic value of plasma renin activity in heart failure
Jiao et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer
WO2007047754A3 (en) Mtor pathway theranostic
DE69333726T8 (de) Glucagonrezeptoren
Contucci et al. Statherin levels in saliva of patients with precancerous and cancerous lesions of the oral cavity: a preliminary report
GB9924957D0 (en) Novel treatment
Kario et al. Dose timing of an angiotensin II receptor blocker/calcium channel blocker combination in hypertensive patients with paroxysmal atrial fibrillation
Harada et al. Androgen deprivation causes truncation of the C‐terminal region of androgen receptor in human prostate cancer LNCaP cells
Strakhova et al. In vitro and in vivo characterization of A‐940894: a potent histamine H4 receptor antagonist with anti‐inflammatory properties
Bianchini et al. Cytosolic [Ca2+] homeostasis and tyrosine phosphorylation of phospholipase C gamma 2 in HL60 granulocytes.
Sultan et al. Fiber type-specific expression of major proteolytic systems in fast-to slow-transforming rabbit muscle
Todorov et al. Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121454

Country of ref document: EP